---
figid: PMC9694305__medicina-58-01572-g002
pmcid: PMC9694305
image_filename: medicina-58-01572-g002.jpg
figure_link: /pmc/articles/PMC9694305/figure/medicina-58-01572-f002/
number: Figure 2
figure_title: ''
caption: Depiction of different pathways that regulate expression of PD-1/PD-L1. The
  PI3K/AKT pathway, WNT pathway, MAPK pathway, NF-ÎºB pathway, JAK/STAT pathway, and
  Hedgehog (Hh) pathway stimulate the expression of PD-1/PD-L1 axis.
article_title: 'Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment
  of Cancer.'
citation: Faisal K. Alkholifi, et al. Medicina (Kaunas). 2022 Nov;58(11):1572.
year: '2022'

doi: 10.3390/medicina58111572
journal_title: Medicina
journal_nlm_ta: Medicina (Kaunas)
publisher_name: MDPI

keywords:
- immune checkpoint
- PD-1
- anti-PD-1 antibody
- TSR-042
- PD-L1
- solid tumors
- cancer
- dostarlimab

---
